PBC plots path to maximize distribution UFC adjusting after acquisition Who's next: Fighters on the rise New HQ represents turning point for UFC Tennis: Advantage technology Baseball: Pace of play Timeline: Charting change Sports fights fatigue First Look podcast: World Congress 2017 Hockey: Technology power play
Upcoming Conferences and Events
May 31 - Jun 1
SBJ/April 4-10, 2011/In Depth
Drug policies take on less prominence
Published April 4, 2011, Page 43
The issue will take on less prominence during the coming labor negotiations compared with prior rounds, in part because both sides have regularly addressed the drug program since the Mitchell Report’s release. In addition to measures calling for a thorough annual review, new substances that become federally banned automatically become prohibited within baseball’s drug program.
“We’ve been revisiting this topic regularly. That was one of the big positive outcomes of the Mitchell Report,” said Rob Manfred, MLB executive vice president for labor relations and human resources. “So, yes, it’s fair to say, this one relative to some other issues on the table will not be as major.”
Human growth hormone, however, is still a particularly thorny problem. A scientifically validated and scalable urine test for HGH remains elusive, despite plenty of attention and money, including from MLB, being thrown at the problem.
MLB last year began a blood test for HGH in the minors, where there is no players union and such matters are not subject to collective bargaining, and it’s likely the issue will be at least discussed for the major league level. The MLBPA, however, has historically shown great resistance to any sort of blood collection for testing purposes, with concerns including player safety and residual effects upon on-field performance.